Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Status: Recruiting
Phase:
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT01975831 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-378

 

This is a multicenter, open-label, study with a standard 3+3 dose-escalation phase, followed by an expansion phase in subjects with solid tumors

 

Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute

Overall PI:
Patrick Ott, MD, Dana Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Meghara Walsh, 617-632-5264, mwalsh10@partners.org

Eligibility Criteria

Inclusion Criteria: - Histologically- or cytologically-confirmed solid tumor with at least one measurable lesion. - Failed to respond to or relapsed following standard treatment, or declined or was not eligible for standard treatment. - ECOG performance status of 0-2. - Anticipated lifespan greater than 6 month. - Adequate organ and marrow function - Able and willing to give valid written informed consent. - Able and willing to give valid written consent for archival tumor samples - Able and willing to give valid written consent for biopsy samples (subjects in the expansion phase only). Exclusion Criteria: - Prior exposure to Tremelimumab or MEDI4736 or other anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies - History of severe allergic reactions to any unknown allergens. - Active or prior autoimmune disease except for autoimmune thyroiditis or vitiligo. - Any prior Grade ≥ 3 immune-related adverse event (irAE) or any prior corticosteroid-refractory irAE. - Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months. - History of sarcoidosis syndrome. - Active or history of inflammatory bowel disease (colitis, Crohn's), diverticulitis, irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea. Active or history of systemic lupus erythematosus or Wegener's granulomatosis. - Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available. - Known immunodeficiency or active HIV. - Participation in any other clinical trial involving another investigational agent within 4 weeks prior to day 1 of the study. - Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study. - Women who are breast feeding or pregnant - Women of childbearing potential not using a medically acceptable means of contraception for the duration of the study.
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients


    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us
award

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.

award

Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters